Chronic News and Research

RSS

Convergence starts Phase II proof of concept study with CNV2197944 in pain associated with PHN

Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines for the treatment of chronic pain, today announces that it has started a Phase II proof of concept study with CNV2197944 in pain associated with post-herpetic neuralgia.

24 Apr 2013

Research explores connection between avocado consumption, CVD risk factors and body composition

The scientific poster session, Interventions for the Treatment and Prevention of Nutrition-Related Diseases, included the poster that won first prize in two American Society for Nutrition Scientific Sessions at Experimental Biology contests- the Student Interest Group Travel Award competition and the Aging and Chronic Disease Research Interest Section Graduate Student Poster competition.

24 Apr 2013

Nanogels to attack lupus: an interview with Dr Look and Dr Fahmy, Yale University

Nanogels are synthetic particles that can be used for drug delivery. They are approximately 100 nm to 200 nm in diameter, and are made from safe, biocompatible materials: a gel-like interior and a lipid exterior.

24 Apr 2013

FDA grants orphan-drug designation to XEN402 for treatment of pain associated with EM

Teva Pharmaceutical Industries Ltd. and Xenon Pharmaceuticals Inc. announced today that the US Food and Drug Administration has granted orphan-drug designation to the investigational drug XEN402 being developed for the treatment of pain associated with erythromelalgia.

24 Apr 2013

Data from MK-5172 Phase II study for treatment of HCV genotype 1 infection to be presented at EASL meeting

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of the latest interim data from a Phase II, multi-center, randomized, dose-ranging clinical trial evaluating the safety and antiviral activity of MK-5172, for the treatment of chronic hepatitis C virus genotype 1 infection.

24 Apr 2013

Sucampo's supplemental new drug application for AMITIZA gets FDA approval

Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. announced today that the United States Food and Drug Administration has approved Sucampo's supplemental new drug application for AMITIZA (lubiprostone) (24 mcg twice daily) as the first and only oral medication for the treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain.

24 Apr 2013

Janssen announces safety results from two Phase 3 studies of simeprevir in hepatitis C patients

Janssen R&D Ireland today announced primary efficacy and safety results from two global Phase 3 studies demonstrating that use of the investigational protease inhibitor simeprevir (TMC435) led to sustained virologic response 12 weeks after the end of treatment (SVR12) in 80 and 81 percent, respectively, of treatment-naive genotype 1 chronic hepatitis C adult patients with compensated liver disease, including all stages of liver fibrosis, when administered once daily with pegylated interferon and ribavirin.

24 Apr 2013

Researchers examine impact of Allies Against Asthma initiative on health care use

Children living in areas where there was wide-ranging and active support for improving outcomes for their chronic asthma were hospitalized less and made fewer visits to the emergency room, when compared with those in other communities.

24 Apr 2013

Home-based health education about diseases most effective, finds study

In the first study of its kind, lay health workers increased screening rates for hepatitis B virus (HBV) and knowledge about the disease among a group of Asian Americans, known as the Hmong, UC Davis researchers have found.

24 Apr 2013

Whole eggs can be part of heart-healthy diet, say researchers

This week at Experimental Biology 2013, scientists from around the world are gathering to share research on a variety of topics, including nutrition and health. Given the growing global burden of chronic disease, there is particular interest in the important role of diet and nutrition in overall health.

24 Apr 2013

New data on Enanta's lead HCV protease inhibitor to be presented at International Liver Congress

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, announced today that new Phase 2b data related to ABT-450, Enanta's lead HCV protease inhibitor identified in its ongoing collaboration with AbbVie, as well as new preclinical data on Enanta's proprietary cyclophilin inhibitor, EDP-546, will be presented at the International Liver Congress, which is the 48th Annual Meeting of the European Association for the Study of the Liver taking place in Amsterdam April 24-28, 2013.

23 Apr 2013

Phase 1 clinical study of rHIgM22 initiated for treatment of multiple sclerosis

Mayo Clinic and Acorda Therapeutics, Inc. today announced that the first patient has been enrolled in the first clinical trial of rHIgM22, a remyelinating antibody being studied for the treatment of multiple sclerosis.

23 Apr 2013

Clinical data on simeprevir for treatment of hepatitis C patients to be presented at EASL meeting

Medivir AB today announces that data will be presented on the investigational protease inhibitor simeprevir (TMC435) for the treatment of genotype 1 hepatitis C patients.

23 Apr 2013

Study: About 42% of screened veterans with blast injuries have irregular hormone levels

Up to 20 percent of veterans returning from Afghanistan and Iraq have experienced at least one blast concussion. New research suggests that nearly half these veterans may have a problem so under-recognized that even military physicians may fail to look for it.

23 Apr 2013

Gilead Sciences to present results from four Phase 3 clinical trials at International Liver Congress 2013

Gilead Sciences, Inc. today announced that detailed results from four Phase 3 clinical trials (NEUTRINO, FISSION, POSITRON and FUSION) evaluating sofosbuvir, the company's investigational once-daily nucleotide NS5B inhibitor for the treatment of chronic hepatitis C virus infection, will be presented this week in oral sessions at the 48th Annual Meeting of the European Association for the Study of the Liver in Amsterdam, The Netherlands.

23 Apr 2013

Merck, Bristol-Myers Squibb to evaluate daclatasvir and MK-5172 for treatment of HCV infection

Merck today announced it has entered into a non-exclusive agreement with Bristol-Myers Squibb to conduct a Phase II clinical trial to evaluate the safety and efficacy of a once-daily oral combination regimen consisting of Bristol-Myers Squibb's investigational NS5A replication complex inhibitor daclatasvir and Merck's investigational NS3/4A protease inhibitor MK-5172 for the treatment of chronic hepatitis C virus infection, genotype 1.

23 Apr 2013

Stratified Medicine Scotland Innovation Centre (SMS-IC) receives funding from the Scottish Funding Council

The University of Glasgow is set to boost its contribution to global medical research and the Scottish economy following the announcement of funding to build a major research centre.

23 Apr 2013

ARCA biopharma, Medtronic to study effectiveness of Gencaro for prevention of atrial fibrillation

ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that it has entered into an agreement with Medtronic, Inc., a leader in medical technologies to improve the treatment of chronic diseases, including cardiac rhythm disorders, to collaborate on ARCA's proposed clinical trial, known as GENETIC-AF, of its lead developmental drug Gencaro (bucindolol hydrochloride).

From Medtronic 23 Apr 2013

Viewpoints: Solving the doctor shortage; Can Gov. Scott convince Fla. lawmakers to accept Medicaid expansion?

With every new report about the recent slowdown in health-care spending there is speculation in the media that the problem of rising health costs has somehow been solved or cut down to size.

23 Apr 2013

William Meehan wins AMSSM Foundation-ACSM Foundation Clinical Research Grant to study brain injury

William Meehan, MD, is the first recipient of the AMSSM Foundation-ACSM Foundation Clinical Research Grant for his research titled "A Randomized, Double-Blind, Placebo-Controlled Trial of Transcranial Light Emitting Diode Therapy for the Treatment of Chronic Concussive Brain Injury."

23 Apr 2013

Chronic News and Research

Convergence starts Phase II proof of concept study with CNV2197944 in pain associated with PHN

Research explores connection between avocado consumption, CVD risk factors and body composition

Nanogels to attack lupus: an interview with Dr Look and Dr Fahmy, Yale University

FDA grants orphan-drug designation to XEN402 for treatment of pain associated with EM

Data from MK-5172 Phase II study for treatment of HCV genotype 1 infection to be presented at EASL meeting

Sucampo's supplemental new drug application for AMITIZA gets FDA approval

Janssen announces safety results from two Phase 3 studies of simeprevir in hepatitis C patients

Researchers examine impact of Allies Against Asthma initiative on health care use

Home-based health education about diseases most effective, finds study

Whole eggs can be part of heart-healthy diet, say researchers

New data on Enanta's lead HCV protease inhibitor to be presented at International Liver Congress

Phase 1 clinical study of rHIgM22 initiated for treatment of multiple sclerosis

Clinical data on simeprevir for treatment of hepatitis C patients to be presented at EASL meeting

Study: About 42% of screened veterans with blast injuries have irregular hormone levels

Gilead Sciences to present results from four Phase 3 clinical trials at International Liver Congress 2013

Merck, Bristol-Myers Squibb to evaluate daclatasvir and MK-5172 for treatment of HCV infection

Stratified Medicine Scotland Innovation Centre (SMS-IC) receives funding from the Scottish Funding Council

ARCA biopharma, Medtronic to study effectiveness of Gencaro for prevention of atrial fibrillation

Viewpoints: Solving the doctor shortage; Can Gov. Scott convince Fla. lawmakers to accept Medicaid expansion?

William Meehan wins AMSSM Foundation-ACSM Foundation Clinical Research Grant to study brain injury

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News